Keyphrases
Stem Cells
100%
Multiple Myeloma
100%
Marrow
100%
Transplant Patients
100%
Autografting
100%
Peripheral Blood Stem Cell Transplantation
100%
Previously Untreated
100%
Allogeneic Bone Marrow Transplantation
72%
High Dose
18%
Progression-free Survival
18%
Interferon-α (IFN-α)
18%
Overall Survival
9%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
9%
Engraftment
9%
Median Overall Survival
9%
Prognostic Factors
9%
Survival Probability
9%
Survival Outcomes
9%
Platelet Recovery
9%
Complete Remission
9%
Granulocyte Colony-stimulating Factor (G-CSF)
9%
Induction Treatment
9%
Untreated Patients
9%
Short Stay
9%
Days in Hospital
9%
Melphalan
9%
Neutrophil Recovery
9%
Sequential Study
9%
Cell Tolerance
9%
Pharmacology, Toxicology and Pharmaceutical Science
Arsphenamine
100%
Overall Survival
100%
Progression Free Survival
100%
Multiple Myeloma
100%
Interferon
100%
Remission
50%
Granulocyte Colony Stimulating Factor
50%
Melphalan
50%
Immunology and Microbiology
Stem Cell Transplant
100%
Stem Cell
100%
Multiple Myeloma
100%
Peripheral Blood Stem Cell
91%
Bone Marrow Transplantation
66%
Interferon Type I
16%
Overall Survival
16%
Progression Free Survival
16%
Drug Megadose
16%
Engraftment
8%
Platelet
8%
Arm
8%
Granulocyte Colony-Stimulating Factor
8%
Neutrophil
8%
Nursing and Health Professions
Transplantation
100%
Multiple Myeloma
100%
Bone Marrow Transplantation
66%
Progression Free Survival
16%
Drug Megadose
16%
Overall Survival
16%
Arsphenamine
16%
Interferon
16%
Remission
8%
Engraftment
8%
Granulocyte Colony Stimulating Factor
8%
Melphalan
8%
Neuroscience
Stem Cell
100%
Interferon
14%
Arsphenamine
14%
Melphalan
7%
Granulocyte Colony-Stimulating Factor
7%
Platelet
7%